

# SECOND MEETING OF THE PANDEMIC INFLUENZA PREPAREDNESS (PIP) FRAMEWORK 2016 REVIEW GROUP 19 February 2016, Geneva, Switzerland

# Report of the Second Meeting of the Pandemic Influenza Preparedness (PIP) Framework 2016 Review Group

#### ORGANIZATION AND PROCESS OF THE MEETING

- 1. The second meeting of the Review Group was held by teleconference on 19 February 2016, 12h00-14h00 Central European Time (CET), with the following agenda:
  - 1. Welcome by Chair
  - 2. Presentation by the subgroups on the key areas of work, documents reviewed and challenges identified to improving implementation of the PIP Framework
    - a. WG1: virus-sharing including genetic sequence data
    - b. WG2: benefit sharing
    - c. WG3: governance and linkages with other instruments
  - 3. Identify analysis needed to support the review, and key informants to inform the deliberations
  - 4. Next steps & next meetings

#### **OPENING OF THE MEETING**

2. Dr Christine Kaseba-Sata, Chair of the Review Group welcomed members to the call and outlined the agenda.

#### REPORTS OF THE WORKING GROUPS

WG1: Virus sharing, including genetic sequencing data

- 3. The virus-sharing working group presented their progress thus far.
- 4. Members of the RG highlighted a number of key issues in virus sharing, including the impact of genetic sequencing data (GSD) on the PIP Framework.
- 5. The Secretariat provided an overview of the work to date of the AG and its technical working group on GSD.

#### WG2: Benefit sharing

- 6. The benefit sharing working group presented its work to date focused on SMTA 2 agreements, partnership contributions and collateral benefits.
- 7. Members of the RG raised a number of suggestions for improving the benefit sharing system and developing good quality metrics for evaluating its efficacy.

#### WG3: Governance and Linkages

- 8. The working group on governance and linkages with other instruments presented its work.
- 9. Suggestions for improving governance and exploring potential linkages with other legal and policy agreements were highlighted.

#### IDENTIFY ANALYSIS NEEDED AND INFORMANTS TO BE INTERVIEWED

- 10. The RG discussed areas in which they may need analysis to be conducted either by the Secretariat or by others.
- 11. The RG discussed potential informants to be interviewed from a range of stakeholders.

#### PROCESS FOR STAKEHOLDER FEEDBACK

12. The RG agreed on a process for soliciting both oral and written feedback from all stakeholders.

#### TIMELINE AND NEXT STEPS

- 13. The Secretariat shared a proposed timeline and key milestones.
- 14. An extra face-to-face meeting was agreed, to be held in early May.
- 15. It was agreed that members of the RG would remain in their current working groups until the next meeting.
- 16. The next meeting is to be held from 30 March through 1 April in Geneva, Switzerland.

\*\*\*\*

# PANDEMIC INFLUENZA PREPAREDNESS (PIP) FRAMEWORK REVIEW GROUP

### 19 FEBRUARY 2016

## **Review Group Members**

<b>Review Group Members</b>	Affiliation
Professor William Kwabena	Head of Virology Department, Noguchi Memorial
Ampofo	Institute for Medical Research, University of Ghana,
	Accra, Ghana
Dr Christine Mwelwa Kaseba-	Former WHO Goodwill Ambassador against Gender-
Sata (Chair)	based Violence, Zambia
Dr Frances McGrath	Chief Advisor, Clinical Leadership, Protection and
	Regulation, Ministry of Health, New Zealand
Dr Talat Mokhtari-Azad,	Director, Iranian National Influenza Center
Ms Johanne Newstead	Head of Food Policy, Public Health Directorate,
	Department of Health, United Kingdom
Dr Theresa Tam	Deputy Chief Public Health Officer of the Public Health
	Agency of Canada
Dr Viroj Tangcharoensathien	Senior Adviser, International Health Policy Program,
	Ministry of Public Health, Thailand
Prof Makarim Wibisono	United Nations Special Rapporteur on Palestinian
	Territories Occupied Since 1967